Adding Pembrolizumab to Chemotherapy Results in Improved PFS and OS in Patients with Advanced and Recurrent Cervical Cancer Regardless of Bevacizumab Use By Ogkologos - November 25, 2024 849 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the subgroup analysis of the KEYNOTE-826 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR “Hero” Nurses Plan Wedding In 24 Hours So Dying Patient Can... May 10, 2019 Breast Cancer Patient Turns Hospital Robes Into Fashion with ‘Radiation Runway’ February 1, 2022 Osimertinib Improves Survival in Advanced Lung Cancer with EGFR Mutations December 12, 2019 ALK Mutations and Amplifications are Independent Predictors of Poorer Survival in... June 24, 2021 Load more HOT NEWS New on NCI’s Websites for March 2025 People with Cancer Say Access to Their Clinical Notes Is Valuable Efficacy of Tivozanib Monotherapy in the Post-ICI Setting Among Patients with... EMA Recommends Extension of Therapeutic Indications for Tisagenlecleucel
